Abstract 4705
Background
Falls are one of the best safety indicators in hospitalized cancer patients. In 2013, a security group was created to promote a culture for patient safety, to prevent, register and analyses falls at 3 cancer centers of Catalan Institute of Oncology. WHO defined falls as the result of an incident that precipitates the patients down involuntarily, includes slipping, tripping and loss of body balance. A systematic review by Wildes (2015), risk factors for hospitalized cancer patients are different from the general patient. Objective: Identify predisposing factors to fall and define the profile of the hospitalized cancer patient with higher risk to fall.
Methods
A cross-sectional, multisite study. Inclusion: patients hospitalized in 3 centers during 2017. Data recruited as voluntary report of falls in a computerized system. Variables: socio-demographic, clinical and environmental factors.
Results
118 falls were reported; 48(40.68%) in Hospitalet; 36(30.51%) in Badalona and 34(28.81%) in Girona. Falls rate was 2.53‰, with lesion was 0.41‰ and severe lesion was 1.35% in one center. Nurses initially classified patients according to Stratify®: high risk 68(59.13%) and 47(40.87%) low-risk. A previous history of fall in last 6 months was for 18(15.25%). By diagnosis 39(33.06%) was lung and head-neck, hematologic 27(22.88%) and colorectal & GI 22(18.68%). The main cause of fall were loss of balance 31(26.50%), lack of strength/ weakness 26(22.22%) and slide 20(17.09%). Location at the hospital was 65 (55.08%) in oncology services, 29(24.58%) in hematology unit and 24(20.34%) in palliative care. Contributing factors was a risky medication 113(96.58%). Factors as being alone 69(58.47%), impairment of mobility 86(73.5%) and patient does not perceived any risk 101(89.38%).
Conclusions
Lung or head-neck neoplasia, medication of risk, mobility problems and the low perception of risk were the common factors resulting associated with a fall. Pautex 2008 indicated a similar rate than our for cancer patients. Room to improve for identification of the patient according to their risk is not enough but, some activities after assessment are needed. Stratify® does not fit properly to define factors related to cancer like anemia, fatigue, chemotherapy or pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2671 - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
Presenter: Ayako Nakashoji
Session: Poster Display session 3
Resources:
Abstract
2650 - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer
Presenter: Sun-Ae Park
Session: Poster Display session 3
Resources:
Abstract
1462 - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
Presenter: Lisha Ying
Session: Poster Display session 3
Resources:
Abstract
5787 - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.
Presenter: Raimondo Di Liello
Session: Poster Display session 3
Resources:
Abstract
5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Dimitris Mavroudis
Session: Poster Display session 3
Resources:
Abstract
5286 - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Presenter: Silvia Calabuig-Fariñas
Session: Poster Display session 3
Resources:
Abstract
5781 - Exosomes in NSCLC as a source of biomarkers
Presenter: Elena Duréndez
Session: Poster Display session 3
Resources:
Abstract
1447 - The role of Pim-1 in the development and progression of papillary thyroid carcinoma
Presenter: Xin Zhu
Session: Poster Display session 3
Resources:
Abstract
1323 - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 3
Resources:
Abstract
3290 - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling
Presenter: Josef Srovnal
Session: Poster Display session 3
Resources:
Abstract